JP2002531826A - 新形成診断法 - Google Patents

新形成診断法

Info

Publication number
JP2002531826A
JP2002531826A JP2000585653A JP2000585653A JP2002531826A JP 2002531826 A JP2002531826 A JP 2002531826A JP 2000585653 A JP2000585653 A JP 2000585653A JP 2000585653 A JP2000585653 A JP 2000585653A JP 2002531826 A JP2002531826 A JP 2002531826A
Authority
JP
Japan
Prior art keywords
cgmp
antibody
sample
pde
neoplastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000585653A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531826A5 (https=
Inventor
リ リュー
ビン ズー
ハン リ
ダブリュー ジョセフ トンプソン
ゲイリー エイ ピアッツァ
リファット パムック
Original Assignee
セル パスウェイズ インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セル パスウェイズ インコーポレイテッド filed Critical セル パスウェイズ インコーポレイテッド
Publication of JP2002531826A publication Critical patent/JP2002531826A/ja
Publication of JP2002531826A5 publication Critical patent/JP2002531826A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2000585653A 1998-11-25 1999-11-24 新形成診断法 Pending JP2002531826A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US20066298A 1998-11-25 1998-11-25
US20002598A 1998-11-25 1998-11-25
US09/200,662 1998-11-25
US09/200,025 1998-11-25
PCT/US1999/028099 WO2000033067A1 (en) 1998-11-25 1999-11-24 Method for diagnosing neoplasia

Publications (2)

Publication Number Publication Date
JP2002531826A true JP2002531826A (ja) 2002-09-24
JP2002531826A5 JP2002531826A5 (https=) 2010-07-01

Family

ID=26895400

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000585653A Pending JP2002531826A (ja) 1998-11-25 1999-11-24 新形成診断法

Country Status (4)

Country Link
EP (1) EP1133689A4 (https=)
JP (1) JP2002531826A (https=)
AU (1) AU1833000A (https=)
WO (1) WO2000033067A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6794192B2 (en) 2000-06-29 2004-09-21 Pfizer Inc. Target
GB0016009D0 (en) * 2000-06-29 2000-08-23 Pfizer Ltd Target

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0687739A (ja) * 1991-03-08 1994-03-29 Fgn Inc 前癌性病変治療剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5401774A (en) * 1991-03-08 1995-03-28 University Of Arizona Method for treating patients with precancerous lesions by administering substituted sulfonyl idenyl acetic and propionic acids and esters to patients with lesions sensitive to such compounds
ES2333691T3 (es) * 1993-05-27 2010-02-26 Board Of Regents Of The University Of Washington Union a gmp ciclica, materiales de fosfodiesterasa especificos a gmp ciclicos y metodos.
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
IL132366A0 (en) * 1998-10-15 2001-03-19 Cell Pathways Inc Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0687739A (ja) * 1991-03-08 1994-03-29 Fgn Inc 前癌性病変治療剤

Also Published As

Publication number Publication date
AU1833000A (en) 2000-06-19
EP1133689A4 (en) 2002-10-30
EP1133689A1 (en) 2001-09-19
WO2000033067A1 (en) 2000-06-08

Similar Documents

Publication Publication Date Title
JP2020002164A (ja) ファルネシルトランスフェラーゼ阻害剤を用いて癌患者を治療する方法
EP2838998B1 (en) Egfr and ros1 in cancer
JP2010246558A (ja) 乳癌の同定、評価、予防、および治療のための組成物、キットおよび方法
JP2009523410A (ja) 遺伝子転写に対するｆｇｆｒ３の阻害剤の効果
JP2002503822A (ja) 癌の治療法
US9523691B2 (en) Use of the olfactomedin-4 protein (OLFM4) in colorectal cancer diagnosis
US6130053A (en) Method for selecting compounds for inhibition of neoplastic lesions
KR101928618B1 (ko) Tk1 단백질의 발현이 항진된 결장직장암 환자에 대한 치료효과 예측 방법
US7432051B2 (en) Erythropoietin and erythropoietin receptor expression in human cancer
JP2002531826A (ja) 新形成診断法
BRPI0608679A2 (pt) métodos para detectar células neoplásicas não viáveis em um indivìduo, para avaliar e/ou monitorar uma condição neoplásica e a efetividade de um regime de tratamento terapêutico de neoplasma em um indivìduo e para tratar uma condição neoplásica e um cáncer metastásico em um indivìduo, kit diagnóstico para uma amostra biológica, uso de uma molécula interativa, composição farmacêutica, e, agente
JP2002517209A (ja) 子宮内膜症の診断および処置におけるプロサイモシンの使用
EP2732287B1 (en) Methods of prognosing chronic lymphocytic leukemia
JP3725800B2 (ja) 化合物の腫瘍形成を阻害する可能性をスクリーニングする方法及びその化合物を含む医薬組成物
US6875575B1 (en) Diagnostic methods for neoplasia
JP2005509159A (ja) 患者が１７−１ａ抗原を標的とする治療薬により治療することのできる癌に苦しんでいるかどうかを測定する方法
Yoo et al. Expression of c-kit and p53 in non-small cell lung cancers
JP4025609B2 (ja) 治療効果判定マーカー
US20090098544A1 (en) Marker molecules associated with lung tumors
US20030044861A1 (en) Method for diagnosing neoplasia
US20250383345A1 (en) Methods and agents for determining patient status
US8354243B2 (en) Method for determining presence of cancer in a sample by assaying for expression of ECSA/DPPA-2 nucleotide sequences
KR100644365B1 (ko) 신생물의 병소부위를 억제하는 화합물의 동정방법 및 상기 화합물을 함유하는 약제학적 조성물
JP2014168466A (ja) ヒト固形腫瘍における遺伝子欠失及び突然変異ａｌｋキナーゼ
Chiriboga et al. Stromal Cell–Derived Factor-1A and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061122

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100129

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100430

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100430

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101129

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110427